About

Patricia Juang is an Associate Clinical Professor of Medicine at UC San Diego. Her research focuses on inpatient diabetes management, electronic health record-based decision-making support, and glycemic control. She has contributed to the review of intravenous and subcutaneous electronic glucose management systems and has published work on reducing hypoglycemia rates in hospital settings. Her publications also include studies on insulin sensitivity, reproductive medicine, and ophthalmology. Juang's work involves applying clinical and translational research to improve inpatient care and diabetes management practices.

Research topics

• Medicine
• Intensive care medicine
• Computer Science
• Internal medicine
• Nursing
• Medical emergency
• Database

Selected publications

• Inpatient Insulin Dosing Calculators

  Diabetes Spectrum · 2025-08-01 · 2 citations

  articleOpen access

  Inpatient insulin calculators offer the potential to improve blood glucose management, simplify workflow, and address the growing demand for inpatient diabetes care. Implementation of computerized insulin protocols remains a challenge at individual institutions.

  PublisherOA PDFDOI

• Electronic Health Record–Based Decision-Making Support in Inpatient Diabetes Management

  Current Diabetes Reports · 2022 · 20 citations

  • Medicine
  • Intensive care medicine
  • Medical emergency

  PURPOSE OF REVIEW: This review discusses ways in which the electronic health record (EHR) can offer clinical decision support (CDS) tools for management of inpatient diabetes and hyperglycemia. RECENT FINDINGS: The use of electronic order sets can help providers order comprehensive basal bolus insulin regimens that are consistent with current guidelines. Order sets have been shown to reduce insulin errors and hypoglycemia rates. They can also help set glycemic targets, give hemoglobin A1C reminders, guide weight-based dosing, and match insulin regimen to nutritional profile. Glycemic management dashboards allow multiple variables affecting blood glucose to be shown in a single view, which allows for efficient evaluation of glucose trends and adjustment of insulin regimen. With the use glycemic management dashboards, active surveillance and remote management also become feasible. Hypoglycemia prevention and management are another part of inpatient diabetes management that is enhanced by EHR CDS tools. Furthermore, diagnosis and management of diabetic ketoacidosis and hyperglycemia hyperosmolar state are improved with the aid of EHR CDS tools. The use of EHR CDS tools helps improve the care of patients with diabetes and hyperglycemia in the inpatient hospital setting.

  PublisherOA PDFDOI

• Review of Intravenous and Subcutaneous Electronic Glucose Management Systems for Inpatient Glycemic Control

  Current Diabetes Reports · 2020 · 20 citations

  • Computer Science
  • Medicine
  • Intensive care medicine
  PublisherDOI

• Practical Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital

  2019-01-01

  book-chapter

  Preview

  PublisherDOI

• How Low Can You Go? Reducing Rates of Hypoglycemia in the Non-critical Care Hospital Setting

  Current Diabetes Reports · 2017-07-28 · 18 citations

  reviewSenior author
  PublisherDOI

• Impact of a Hypoglycemia Reduction Bundle and a Systems Approach to Inpatient Glycemic Management

  Endocrine Practice · 2014-12-23 · 53 citations

  article
  PublisherDOI

• Figure 3, Kaplan-Meier Curve of Time to Secondary Endpointa in the PROactive Study

  2013-09-04

  article1st authorCorresponding
  Publisher

• Testosterone with Dutasteride, but Not Anastrazole, Improves Insulin Sensitivity in Young Obese Men: A Randomized Controlled Trial

  The Journal of Sexual Medicine · 2013-11-06 · 36 citations

  article1st author

  INTRODUCTION: Testosterone (T) administration to men increases T, estradiol (E2), dihydrotestosterone (DHT), and fat-free mass (FFM), and decreases fat mass (FM) but does not consistently improve insulin sensitivity (IS). AIM: The aim of this study was to examine the effects of T administration in obese, nondiabetic men on body composition and IS, and to determine if inhibition (i) of metabolism of T to E2 with anastrazole or to DHT with dutasteride alters these effects. METHODS: This was a 98-day randomized, double-blind, parallel group, placebo-controlled trial of 57 men, 24-51 year, free T in the lower 25% of normal range (<0.33 nmol/L), body mass index ≥ 30.0 kg/m(2). Subjects were randomized to one of four groups: (i) placebo: gel, pills, and injection; (ii) T/DHT/iE2: T gel, anastrazole, and acyline (gonadotropin releasing-hormone antagonist to suppress endogenous T); (iii) T/iDHT/E2: T gel, dutasteride, and acyline; (iv) T/DHT/E2: T gel, placebo pills, and acyline. MAIN OUTCOME MEASURES: Main outcome measures are insulin sensitivity as percent change (%Δ) in glucose disposal rates (GDR) from a two-step euglycemic clamp (GDR1 and 2), and %FM and %FFM by dual X-ray absorptiometry scan. RESULTS: Insulin Sensitivity: %Δ GDR1 differed across groups (P = 0.02, anova) and was significantly higher in the dutasteride (T/iDHT/E2) compared with the placebo and T gel (T/DHT/E2) groups. %ΔGDR2 was higher in the dutasteride (T/iDHT/E2) compared with the anastrazole (T/DHT/iE2) group. Body Composition: T gel alone (T/DHT/E2) or with dutasteride (T/iDHT/E2) significantly increased %FFM (P < 0.05) and decreased %FM (P < 0.05). There was no change in %FFM or %FM after placebo or anastrazole (T/DHT/iE2). CONCLUSIONS: The combination of T plus dutasteride improved body composition and IS while T alone improved body composition but not IS, suggesting that when T is administered to men, reduction to DHT attenuates the beneficial effects of aromatization to E2 on IS but not body composition.

  PublisherDOI

• Figure 5, Change in Mean A1C Over 3 Month Treatment Period

  2013-09-04

  article1st authorCorresponding
  Publisher

• Table 8, Summary of Results of 30-week Trials of Exenatide in Combination with Metformin, Sulfonylurea or Both(69-71)

  2013-09-04

  article1st authorCorresponding
  Publisher

Frequent coauthors

• Robert R. Henry

  Medical University of South Carolina

  26 shared

• Andrea D. Coviello

  Mayo Clinic in Florida

  6 shared

• Susan Peng

  4 shared

• Karen L. Herbst

  The Roxbury Institute

  4 shared

• Kristen Kulasa

  4 shared

• Robert R. Henry

  4 shared

• Aaron S. Field

  University of Wisconsin–Madison

  2 shared

• Ed Fink

  Center for Innovation

  2 shared

Labs

• Patricia JuangPI